Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Specialty Intermediates To Discontinue Operational Activities
Reportedly, the closure is expected to result in the loss of 37 jobs at DSI. DSM has asked the local Works Council for advice on the planned closure.
Reportedly, the closure is expected to result in the loss of 37 jobs at DSI. DSM has asked the local Works Council for advice on the planned closure.
The company claims that it is simple to use and employs analytical methodology based on established pharmacopoeial techniques for transdermal patches. It provides information that allows developers to
In the study, Picoplatin, in combination with 5-fluorouracil and leucovorin (FOLPI regimen), was associated with a reduction in neurotoxicity compared to oxaliplatin given in combination with 5-fluorouracil and
Pharming has submitted the MAA for Rhucin to the European Medicines Agency in September 2009, and the CHMP has issued the Day 120 List of Questions(LoQ) on 21
Michael French, president and CEO of MDRNA, said: “While our focus remains the development of RNAi-based therapeutics, we believe that the intranasal assets from our predecessor company, Nastech
SOCMA has reported that, in the notice, EPA identified classes of facilities within the industry ‘for which the agency plans to develop, as necessary, a proposed regulation identifying
Biocon is in talks with BiotecCorp to manufacture Biopharmaceutical products and formulation, within Malaysia’s Nusajaya, Iskandar Malaysia, known as Bio-XCell Ecosystem. Biocon is also developing biotechnology infrastructure in
Initially, the company plans to market IoGen through its own retail web site, which is currently being developed by Atech Solutions. In preparation of the launch, Symbollon has
The company claims that the Seal-Scan has been a successful inspection solution for many types of pouches and flexible packaging. Applications included in the system are: medical device
Anadys has also announced that all patients have commenced dosing in the second dose cohort, 400mg bid. With patient enrollment in this cohort completed, the company has accelerated